Fractyl Health (NASDAQ:GUTS) CFO Buys 20,000 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) CFO Weber Lara Smith purchased 20,000 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were bought at an average price of $0.69 per share, for a total transaction of $13,800.00. Following the completion of the transaction, the chief financial officer directly owned 20,000 shares in the company, valued at approximately $13,800. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fractyl Health Stock Performance

GUTS stock traded down $0.01 during mid-day trading on Tuesday, reaching $0.66. The company had a trading volume of 1,197,253 shares, compared to its average volume of 4,031,295. Fractyl Health, Inc. has a one year low of $0.38 and a one year high of $2.90. The stock has a market capitalization of $105.36 million, a P/E ratio of -0.51 and a beta of 2.34. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock’s 50-day simple moving average is $0.67 and its two-hundred day simple moving average is $1.08.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. Research analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new stake in shares of Fractyl Health in the third quarter valued at $19,298,000. 683 Capital Management LLC grew its holdings in shares of Fractyl Health by 30.1% during the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after buying an additional 1,397,620 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Fractyl Health by 234.9% during the fourth quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after buying an additional 4,156,969 shares in the last quarter. Pale Fire Capital SE raised its position in Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after buying an additional 2,711,103 shares during the period. Finally, Alyeska Investment Group L.P. purchased a new stake in Fractyl Health in the 3rd quarter worth about $8,981,000.

Analysts Set New Price Targets

GUTS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, March 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.